cyclosporine

Paging Pediatric Dermatology to the Emergency Room!
Pediatric Dermatology EmergenciesPediatric dermatologic emergencies are very real, highlights Dr. Kalyani Marathe, Associate Professor of Dermatology and Pediatrics at the University of Cincinnati, who lectured during ODAC 2023. Pediatric dermatologic emergencies represent almost 4% of emergency room visits, and of those, most are related to chronic skin disease, drug eruptions, and infections. Here, we will review some of those …
Pediatric Dermatology Emergencies
Translating Psoriasis Guidelines into Practice
psoriasis guidelinesBefore we dive into our discussion, let’s outline the Guideline-Based Approach to Treatment Selection. The International Psoriasis Council has divided psoriasis treatment classification into 2 groups: Patients who are a candidate for topical therapy, or Patients who are a candidate for systemic therapy Candidates for systemic therapy must meet at least 1 of the following …
psoriasis guidelines
Atopic Dermatitis (AD) Treatment Initiation and Monitoring
atopic dermatitis (AD)During the recent DERM2O22 NP/PA CME conference held July 28-31, 2022, Drs. David Cohen, Brad Glick, and Adam Friedman led a case-based panel discussion on atopic dermatitis (AD) treatment initiation and monitoring. This article provides a summary of their discussion and recommendations.  CASE 1 51-year-old male with a 20-year history of AD. The patient was first seen in September 2015 with BSA …
atopic dermatitis (AD)
The Many Faces of Psoriasis | Part 2
psoriasisDid you know that psoriasis doesn’t just present on the arms, legs, and trunk? It can also appear in non-conventional locations (aka “special site” psoriasis) including the scalp, face, and body folds (such as the axillary, inframammary, and inguinal fields, and intergluteal clefts). In the skin folds, psoriasis is also referred to as “inverse psoriasis.” In darker skin types, the areas …
psoriasis
Tralokinumab-ldrm Therapeutic Cheat Sheet
tralokinumabAtopic dermatitis is a common, chronic, life-altering disease. With its visibility and debilitating pruritus, atopic dermatitis significantly impacts our patients’ quality of life. For those with resistant and extensive disease, we are happy to have numerous new systemic agents at our disposal, one being tralokinumab, an IL-13 antagonist. We continue our series, Therapeutic Cheat Sheet, with a c …
tralokinumab